Community Academic Profiles–

Edward Riley

Back to Profile

In-vitro study to assess the coagulation effects of exogenous oxytocin using thromboelastography.

Contact Information

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Primary Contact:

Alexander Butwick
To view all clinical trials at Stanford, please see the Clinical Trials Directory.

Brief

Oxytocin is normally administered following delivery in pregnant patients to reduce postpartum bleeding by increasing uterine tone. It is unclear whether the use of intravenous oxytocin alters coagulation in pregnant patients. The purpose of the in-vitro study is to assess the coagulation changes of oxytocin in blood samples from pregnant patients using thromboelastrography (TEG). TEG is a point-of-care device which measures the viscoelastic properties of clot formation, and can provide rapid and detailed information about coagulation changes. We aim to collect blood samples from pregnant patients to assess the in-vitro effects of synthetic oxytocin on coagulation using TEG.

Recruiting Status:

Completed

Stanford Recruiting Status:

Completed

Condition(s):

Intervention(s):

  • Procedure: thromboelastography

Phase:

N/A

Eligibility

Ages Eligible for Study:

Any Age to Any Age

Genders Eligible for Study:

Female

Health of Volunteers:

People with the conditions listed in this trial can participate as controls.

Key Inclusion Criteria:

All obstetric patients with singleton pregnancies admitted to the labor and delivery unit at Lucille Packard Childrens
Hospital awaiting elective induction of labor or elective Cesarean delivery.
We will select 25 healthy ASA 1 patients with singleton pregnancies who are scheduled for uncomplicated
elective induction of labor.
Gestational age equal to or greater than 37 weeks.

Key Exclusion Criteria:

Patients with underlying coagulation disorders.
Patients with thrombocytopenia.
Patients with pregnancy-induced hypertension, pre-eclampsia.
Patients admitted for non-elective cesarean section.
Patients in active labor.
Patients requiring the following medications prior to surgery: NSAIDS, aspirin, anticoagulants.
Patients with significant obstetric or medical disease.
No patients <18 years of age will be recruited.

Additional Study Details

Official Title:

In-vitro study to assess the coagulation effects of exogenous oxytocin using thromboelastography.

Anticipated start date:

10/27/2008

Lead Sponsor:

Stanford University

Investigator(s):

Study Type:

Observational

Purpose:

NOTNEEDED

Duration:

Cross-sectional

Selection:

Defined Population

Timing:

Prospective

Total Number to be Enrolled:

25

Total Number to be Enrolled at Stanford:

25

More Information

Trial Unique Id: SU-10242008-1327

Locations & Contacts

Stanford Locations & Contacts:

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Primary Contact:

Alexander Butwick

Non-Stanford Locations:

The Stanford website does not have any locations outside of Stanford listed for this trial. You may want to check clinicaltrials.gov for posible additional locations.

This listing was last updated:

10/20/2009

PLEASE NOTE:

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician. If you do not have a primary care physician please feel free to call the SHC Physician Referral Service at (800) 756-9000 or send an email.

Stanford Medicine Resources:

Footer Links: